NanoViricides, Inc. (NYSE American: NNVC) announced the closing of its previously announced registered direct offering with a single institutional investor, generating aggregate gross proceeds of approximately $2 million before fees and expenses. The offering consisted of 1,333,334 shares of common stock, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase 1,333,334 additional common shares. The securities were priced at $1.50 per share and accompanying warrant. D. Boral Capital LLC acted as exclusive placement agent for the offering.
NanoViricides is a clinical-stage company developing novel nanomaterial-based antiviral therapies. Its lead drug candidate, NV-387, is a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. Another advanced candidate, NV-HHV-1, targets shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The capital raise comes at a critical time as NanoViricides seeks to fund its clinical development programs. The company’s technology platform is based on proprietary nanoviricide technology licensed from TheraCour Pharma, Inc., which enables targeted delivery of antiviral agents. For COVID-19, NanoViricides has two drug candidates: NV-CoV-2 (API NV-387) and NV-CoV-2-R, which encapsulates the FDA-approved drug remdesivir within polymeric micelles. The company believes that NV-CoV-2-R could be approvable if safety is comparable to remdesivir alone.
This financing provides near-term capital to support the company’s operations as it prepares for human trials. However, the company acknowledges the lengthy and capital-intensive nature of drug development, noting that there can be no assurance that any of its candidates will prove safe and effective in clinical trials. The path to regulatory approval remains uncertain, and the company will require substantial additional capital to complete development.
For investors, the offering represents a vote of confidence from an institutional investor, but it also dilutes existing shareholders. The warrants could provide additional capital if exercised. The company’s broad pipeline, covering multiple high-value viral indications including RSV, COVID-19, and influenza, offers potential upside if clinical trials succeed. However, the biotech sector is inherently risky, and NanoViricides faces competition from established antiviral therapies and other novel platforms.
The impact on the industry is significant if NV-387 proves effective as a broad-spectrum antiviral, potentially addressing multiple viral threats with a single drug. This could revolutionize pandemic preparedness and reduce the burden of seasonal respiratory viruses. For now, the company remains focused on advancing its lead candidate into the clinic, with this offering providing the necessary runway to reach key milestones.
For more information, visit the company's newsroom at https://ibn.fm/NNVC and view the full press release at https://ibn.fm/5O81R.
